Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial bit.ly/2MyjKwC 
First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants.
Strong efficacy in Phase 3 UK trial with over 50% of cases attributable to the now-predominant UK variant and the remainder attributable to COVID-19 virus.
Clinical efficacy demonstrated in Phase 2b South Africa trial with over 90% of sequenced cases attributable to prevalent South Africa escape variant.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
